BioCryst Pharmaceuticals, Inc.
BCRX
$8.39
-$0.17-1.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.09M | 32.00K | -26.80M | -14.03M | -12.67M |
| Total Depreciation and Amortization | 329.00K | 331.00K | 2.08M | 311.00K | 320.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.51M | 34.25M | 30.84M | 31.10M | 29.28M |
| Change in Net Operating Assets | 2.38M | -62.13M | -11.33M | -9.13M | -18.30M |
| Cash from Operations | 41.30M | -27.52M | -5.21M | 8.25M | -1.37M |
| Capital Expenditure | -179.00K | -143.00K | -675.00K | -59.00K | -155.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 29.31M | 27.24M | 18.47M | 8.55M | -2.29M |
| Cash from Investing | 29.13M | 27.10M | 17.80M | 8.49M | -2.45M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -76.25M | -516.00K | -356.00K | -556.00K | -402.00K |
| Issuance of Common Stock | 3.43M | 2.40M | -- | 2.09M | 276.00K |
| Repurchase of Common Stock | -- | -- | -581.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -866.00K | -1.35M | -3.08M | -261.00K | -1.84M |
| Cash from Financing | -73.69M | 529.00K | -4.02M | 1.27M | -1.97M |
| Foreign Exchange rate Adjustments | 1.36M | 451.00K | -1.30M | 851.00K | -143.00K |
| Miscellaneous Cash Flow Adjustments | -15.06M | -- | -- | -- | -- |
| Net Change in Cash | -16.96M | 558.00K | 7.26M | 18.86M | -5.93M |